Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
RMC-6236 by Revolution Medicines for Melanoma: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Melanoma. According to GlobalData, Phase I...
RMC-6236 by Revolution Medicines for Gynecological Cancer: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase...
RMC-6236 by Revolution Medicines for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase III for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
RMC-6236 by Revolution Medicines for Non-Small Cell Lung Cancer: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase II for Non-Small Cell Lung Cancer. According to...
RMC-6236 by Revolution Medicines for Solid Tumor: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
RMC-9805 by Revolution Medicines for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
RMC-9805 is under clinical development by Revolution Medicines and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
RMC-5552 by Revolution Medicines for Head And Neck Cancer: Likelihood of Approval
RMC-5552 is under clinical development by Revolution Medicines and currently in Phase I for Head And Neck Cancer. According to...
RMC-5552 by Revolution Medicines for Pancreatic Cancer: Likelihood of Approval
RMC-5552 is under clinical development by Revolution Medicines and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
RMC-5552 by Revolution Medicines for Colorectal Cancer: Likelihood of Approval
RMC-5552 is under clinical development by Revolution Medicines and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
RMC-5552 by Revolution Medicines for Ovarian Cancer: Likelihood of Approval
RMC-5552 is under clinical development by Revolution Medicines and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
RMC-5552 by Revolution Medicines for Lung Cancer: Likelihood of Approval
RMC-5552 is under clinical development by Revolution Medicines and currently in Phase I for Lung Cancer. According to GlobalData, Phase...
RMC-9805 by Revolution Medicines for Non-Small Cell Lung Cancer: Likelihood of Approval
RMC-9805 is under clinical development by Revolution Medicines and currently in Phase I for Non-Small Cell Lung Cancer. According to...
RMC-9805 by Revolution Medicines for Solid Tumor: Likelihood of Approval
RMC-9805 is under clinical development by Revolution Medicines and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
RMC-9805 by Revolution Medicines for Colorectal Cancer: Likelihood of Approval
RMC-9805 is under clinical development by Revolution Medicines and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Revolution Medicines's RMC-6291?
RMC-6291 is a small molecule commercialized by Revolution Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer....
Risk adjusted net present value: What is the current valuation of Revolution Medicines's RMC-6236?
RMC-6236 is a small molecule commercialized by Revolution Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer....
RMC-6291 by Revolution Medicines for Non-Small Cell Lung Cancer: Likelihood of Approval
RMC-6291 is under clinical development by Revolution Medicines and currently in Phase II for Non-Small Cell Lung Cancer. According to...
RMC-6291 by Revolution Medicines for Solid Tumor: Likelihood of Approval
RMC-6291 is under clinical development by Revolution Medicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase...